Charles Schwab Investment Management Inc Axcella Health Inc. Transaction History

Charles Schwab Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.41 - $2.77 $25,732 - $50,552	18,250 New	18,250 $38,000
Q3 2021 Nov 16, 2021	SELL	$2.98 - $4.31 $30,708 - $44,414	-10,305 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.08 - $5.13 $64,134 - $106,821	-20,823 Reduced 66.89%	10,305 $42,000
Q1 2021 May 17, 2021	SELL	$4.55 - $6.72 $47,693 - $70,439	-10,482 Reduced 25.19%	31,128 $149,000
Q3 2020 Nov 13, 2020	BUY	$4.12 - $5.91 $42,918 - $61,564	10,417 Added 33.4%	41,610 $193,000
Q2 2020 Aug 14, 2020	BUY	$2.94 - $7.7 $41,703 - $109,224	14,185 Added 83.4%	31,193 $173,000
Q4 2019 Feb 07, 2020	BUY	$3.08 - $5.9 $52,384 - $100,347	17,008 New	17,008 $69,000

61.6K

Ticker AXLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,500,896
Description
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrenc...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.